Isis Accused Of Hiding Cholesterol Drug's Safety Risks

Law360, New York (January 2, 2013, 3:34 PM EST) -- A putative class action launched Friday in California federal court alleges Isis Pharmaceuticals Inc. misled investors over the safety and effectiveness of cholesterol disorder treatment Kynamro, which U.S. Food and Drug Administration researchers warned in October had potentially serious side effects.

Although an FDA advisory committee eventually recommended that the agency approve the drug, which Isis is developing with Genzyme Corp., the suit launched by Isis investor Morad Ghoodshim alleges the company's senior management failed to disclose that Kynamro’s clinical trials couldn't sufficiently demonstrate the drug’s...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Ghoodshim v. Isis Pharmaceuticals, Inc. et al


Case Number

3:12-cv-03071

Court

California Southern

Nature of Suit

Securities/Commodities

Judge

Cathy Ann Bencivengo

Date Filed

December 27, 2012

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.